• Accustem Sciences posted a net loss of $485,883 for three months ended March 31, 2026, widening 10% from a year earlier; operating loss also widened 10% to $485,883.
• Research and development expenses more than quadrupled to $119,525, up 322%, while general and administrative costs fell 11% to $366,358.
• Cash and cash equivalents ended period at $12,207, down from $13,929 at start of quarter; cash used in operating activities rose to $374,176 from $290,182.
• Company reiterated plan to launch MSC lung test for clinical use in early 2027, with transfer of MSC to partner lab EmeritusDx under way ahead of CLIA certification and reimbursement efforts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Accustem Sciences Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-023742), on May 15, 2026, and is solely responsible for the information contained therein.